Application Number Funding Recommendation Title Score DR2A-05415 Recommended MSC engineered to produce BDNF for the treatment of Huntington's disease 87 DR2A-05309 Recommended Genetic Re-programming of Stem Cells to Fight Cancer 84 DR2A-05302 Recommended Treatment of osteoporosis with endogenous Mesenchymal stem cells 80 DR2A-05423 Recommended Phase I study of IM Injection of VEGF-Producing MSC for the Treatment of Critical Limb Ischemia 79 DR2A-05736 Recommended Neural stem cell transplantation for chronic cervical spinal cord injury 79 DR2A-05394 Recommended Human Embryonic Stem Cell-Derived Cardiomyocytes for Patients with End Stage Heart Failure 68 DR2A-05320 Not recommended Progenitor Cells Secreting GDNF for the Treatment of ALS 64 DR2A-05410 Not recommended A CIRM Disease Team to Develop Allopregnanolone for Prevention and Treatment of Alzheimer's Disease 63 DR2A-05416 Not recommended Restoration of memory in Alzheimer’s disease: a new paradigm using neural stem cell therapy 61 DR2A-05272 Not recommended hESC-derived NPCs Programmed with MEF2C for Cell Transplantation in Parkinson’s Disease 0 DR2A-05288 Not recommended Genetically Engineered Mesenchymal Stem Cells for the Treatment of Vertebral Compression Fractures. 0 DR2A-05739 Not recommended Retinal progenitor cells for treatment of retinitis pigmentosa 53 DR2A-05365 Not recommended A monoclonal antibody that depletes blood stem cells and enables chemotherapy free transplants 53 DR2A-05368 Not recommended Development of a Targeted Therapy to Repair Osteoporosis-Related Hip Fractures 0 DR2A-05352 Not recommended A New Therapeutic to Reduce CSC Frequency in Breast Cancer 0 DR2A-05298 Not recommended Airways for Children 0 DR2A-05735 Not recommended Allogeneic Cardiac-Derived Stem Cells for Patients Following a Myocardial Infarction 45 DR2A-05327 Not recommended Stem Cell Gene Therapy for HIV in AIDS Lymphoma Patients 0 DR2A-05373 Not recommended Recombinant Bispecific Antibody Targeting Cancer Stem Cells for the Therapy of Glioblastoma 0 DR2A-05737 Not recommended Phase 3 enabling program for a small molecule in treatment resistant depression and major depressive disorder 0